Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Linifanib
As low as
CHF 0.00
In stock
Only %1 left
SYN-1002-M0011 mgCHF 114.00
SYN-1002-M0055 mgCHF 170.00
SYN-1002-M01010 mgCHF 284.00
SYN-1002-M05050 mgCHF 780.00
SYN-1002-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | ABT-869; AL39324; RG-3635 |
| Product Type | Chemical |
| Properties | |
| Formula | C21H18FN5O |
| MW | 375.4 |
| CAS | 796967-16-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | MPVGZUGXCQEXTM-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3β phosphorylation and maybe influencial in AML therapy.
Product References
- Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor: Y. Dai, et al.; J. Med. Chem. 50, 1584 (2007)
Related Products
-
Genistein AG-CN2-0427